Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 Inhibitors in Calcified Aortic Valve Disease
NCT06996223Phase 1Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2025
- Primary completion
- Jun 2027
01
Overview
Phase 1, randomised trial in calcific aortic valve disease (CAVD) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Mean annual variation of peak aortic valve velocity at 48 months. Planned start Jun 2025; status: not yet recruiting.
02
Conditions
calcific aortic valve disease (CAVD)
Beyond the preview
Go deeper on NCT06996223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06996223.